NCT07537738 Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
| NCT ID | NCT07537738 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University People's Hospital |
| Condition | Acute Myeloid Leukemia (AML) |
| Study Type | OBSERVATIONAL |
| Enrollment | 210 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-04-07 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is: • Could be leukemia stem cell used for relapse prediction in acute myeloid leukemia patients with MLL-rearrangement? Leukemia stem cell will be detected at the same time for participants who detected minimal residual disease using bone marrow as part of their regular medical care to answer the question.
Eligibility Criteria
Inclusion Criteria: Acute myeloiud leukemia patients with MLL arrangement aging 6-60 years recieving chemoterapy or allo-geneic hematopoietic stem cell transplantation. Exclusion Criteria: 1. Patients who cannot recieve chemoterapy or allo-geneic hematopoietic stem cell transplantation. 2. Patients who cannot comply with the study.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.